Monthly
US$200
Billed every month
Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution(硫酸镁钠钾口服用浓溶液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 2 applicationsNotification delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders1View records ↓
Under-review filings8View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers40View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 1 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 济川药业集团有限公司 | 济川药业集团有限公司 | 国药准字H20223027 | 2022/01/30 | 177ml：含硫酸镁1.6g、硫酸钠17.5g和硫酸钾3.13g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 40 distinct approval numbers and 40 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京双鹭药业股份有限公司 | 国药准字H20264944 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010100148 | NHSA |
| 广东隆赋药业股份有限公司 | 国药准字H20263215 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g 和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010100290 | NHSA |
| 浙江国镜药业有限公司 | 国药准字H20265417 | 176ml:硫酸镁(按MgSO₄•7H₂O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010104634 | NHSA |
| 广西维威制药有限公司 | 国药准字H20265438 | 176ml:硫酸镁(按MgSO₄·7H₂O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010105237 | NHSA |
| 江西盛翔制药有限公司 | 国药准字H20263795 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g与硫酸钾3.13g | Category B (乙) | XA06ADL397X019010105355 | NHSA |
| 山东朗诺制药有限公司 | 国药准字H20264316 | 176ml:硫酸镁(按MgSO₄·7H₂O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010110323 | NHSA |
| 天盛(厦门)医药科技有限公司 | 国药准字H20265186 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010186658 | NHSA |
| 广东大冢制药有限公司 | 国药准字H20255104 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g。 | Category B (乙) | XA06ADL397X019010100273 | NHSA |
| 武汉同济现代医药科技股份有限公司 | 国药准字H20253056 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010100555 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253543 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010101503 | NHSA |
| 南京正科医药股份有限公司 | 国药准字H20255040 | 176ml:硫酸镁(按MgSO4•7H2O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010101599 | NHSA |
| 河北华晨药业集团有限公司 | 国药准字H20255517 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010102617 | NHSA |
| 河北合渡药业有限公司 | 国药准字H20255028 | 177ml:硫酸镁(按MgSO4 计)1.6g、硫酸钠17.5g和硫酸钾 3.13g | Category B (乙) | XA06ADL397X019010102680 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20255032 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010102753 | NHSA |
| 云鹏医药集团有限公司 | 国药准字H20255175 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010102968 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20253358 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010104145 | NHSA |
| 安徽环球药业股份有限公司 | 国药准字H20255300 | 177ml:硫酸镁(按MgSO₄计)1.600g、硫酸钠17.500g和硫酸钾3.130g | Category B (乙) | XA06ADL397X019010104303 | NHSA |
| 浙江凯润药业股份有限公司 | 国药准字H20255103 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010104649 | NHSA |
| 沈阳天邦药业有限公司 | 国药准字H20255021 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010110021 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20253996 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010183033 | NHSA |
| 苏州朗科生物技术股份有限公司 | 国药准字H20253542 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010183485 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20255051 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010183611 | NHSA |
| 浙江百代医药科技有限公司 | 国药准字H20255524 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010184211 | NHSA |
| 广州市亿源医药有限公司 | 国药准字H20255031 | 176ml:硫酸镁(按MgSO₄·7H₂O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010184691 | NHSA |
| 广州合和医药有限公司 | 国药准字H20256254 | 176ml:硫酸镁(按MgSO₄·7H₂O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010185013 | NHSA |
| 苏州二叶制药有限公司 | 国药准字H20254941 | 176ml:硫酸镁(按MgSO₄·7H₂O计)3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010185068 | NHSA |
| 成都米子生物医药科技有限公司 | 国药准字H20255294 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010185135 | NHSA |
| 武汉同济现代医药科技股份有限公司 | 国药准字H20253056 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010200555 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20253358 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010204145 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20255051 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010283611 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20253062 | 177ml:硫酸镁(以MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾 3.13g | Category B (乙) | XA06ADL397X019010284109 | NHSA |
| 武汉同济现代医药科技股份有限公司 | 国药准字H20253056 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010300555 | NHSA |
| 广州大光制药有限公司 | 国药准字H20249371 | 177ml:硫酸镁(以MgSO₄计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010100548 | NHSA |
| 济川药业集团有限公司 | 国药准字H20223027 | 177ml:硫酸镁(以MgSO4计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010101453 | NHSA |
| 扬子江药业集团上海海尼药业有限公司 | 国药准字H20223102 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010101747 | NHSA |
| IPSEN CONSUMER HEALTHCARE | 国药准字HJ20220094 | 176ml:硫酸镁3.276g、硫酸钠17.510g与硫酸钾3.130g | Category B (乙) | XA06ADL397X019010183508 | NHSA |
| 维生原(厦门)生物科技有限公司 | 国药准字H20249740 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫酸钾3.13g | Category B (乙) | XA06ADL397X019010183535 | NHSA |
| 重庆健能药业集团有限公司 | 国药准字H20249699 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010183692 | NHSA |
| 长春澜江医药科技有限公司 | 国药准字H20249385 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010183864 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20249372 | 177ml:硫酸镁(按MgSO4计)1.6g、硫酸钠17.5g和硫酸钾 3.13g | Category B (乙) | XA06ADL397X019010184221 | NHSA |
| 浙江恒研医药科技有限公司 | 国药准字H20249703 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010184227 | NHSA |
| 南京知和医药科技有限公司 | 国药准字H20249629 | 177ml:硫酸镁(按MgSO₄计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010184650 | NHSA |
| 西藏奥斯必秀医药有限公司 | 国药准字H20249746 | 177ml: 硫酸镁(按MgSO₄计) 1.6g、硫酸钠17.5g和硫酸钾 3.13g | Category B (乙) | XA06ADL397X019010184724 | NHSA |
| 济川药业集团有限公司 | 国药准字H20223027 | 177ml:硫酸镁(以MgSO4计)1.6g、硫酸钠17.5g和硫 | Category B (乙) | XA06ADL397X019010201453 | NHSA |
| 海南斯达制药有限公司 | 国药准字H20266115 | 176ml:硫酸镁(按MgSO₄·7H₂O计)3.276g、硫酸钠17.510g和硫酸钾3.130g | Category B (乙) | XA06ADL397X019010105816 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 8 filings and 7 distinct first applicants.
Generic 6 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 南京海纳医药科技股份有限公司;南京海纳制药有限公司 | CYHS2600391 | Generic | 2026/02/06 | Not stated by source | CDE |
| 辽宁大熊制药有限公司 | CYHS2602246 | Generic | 2026/09/09 | Not stated by source | CDE |
| MAYOLY PHARMA FRANCE;MAYOLY INDUSTRIE | JYHB2600344 | Supplement | 2026/06/24 | Not stated by source | CDE |
| 哈药集团生物工程有限公司 | CYHS2504378 | Generic | 2025/12/24 | Not stated by source | CDE |
| 西洲医药科技（浙江）有限公司;浙江北生药业汉生制药有限公司 | CYHS2502037 | Generic | 2025/06/10 | Not stated by source | CDE |
| 湖北海美纳医药科技有限公司;湖北唯森制药有限公司 | CYHS2501365 | Generic | 2025/04/09 | Not stated by source | CDE |
| 湖北午时药业股份有限公司 | CYHS2501165 | Generic | 2025/03/25 | Not stated by source | CDE |
| MAYOLY PHARMA FRANCE;MAYOLY INDUSTRIE | JYHB2600594 | Supplement | 2026/11/04 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/04Notification delivery
成都亚中生物制药有限责任公司
CYHS2504013
Fact date: 2026/11/04 (Publication date) · Publication date: 2026/11/04 · Site observation date: 2026/11/04
Notification delivered; the specific outcome remains to be checked.
View source · Table row 10 ↗ -
2026/11/04Accepted
MAYOLY PHARMA FRANCE;MAYOLY INDUSTRIE
JYHB2600594
Fact date: 2026/11/04 · Site observation date: 2026/11/05
View source ↗ -
2026/10/26Marketing application approved
湖北民康药业集团有限公司
CYHS2500938 · 国药准字H20266415
Fact date: 2026/10/26 · Publication date: 2026/10/27 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 35 ↗ -
2026/09/09Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy